être évalué pour assurer une stabilité à long terme. Tous les développements de formulation seront effectués dans les installations de Nanopharm à Newport, au Royaume-Uni, qui abritent ses labo- ratoires de R&D pour la formulation et la carac- térisation des produits inhalés et nasaux, et qui soutiennent les jeunes entreprises biotechnolo- giques, les grandes entreprises pharmaceutiques ou les sociétés génériques dans le monde entier. Nanopharm and Leyden Labs enter agreement to develop nasal spray drugs against known and future viruses Last July, Nanopharm, an Aptar Pharma company and leader in contract research and development of orally inhaled and nasally delivered drug products (OINDP) and Leyden Labs, a company targeting commonalities of viral families to protect huma- nity from known and future viruses, announced that they had entered into an agreement to deve- lop nasal sprays that may provide broad protection against respiratory viruses, combining Leyden Labs’ portfolio and Nanopharm’s expertise in the development of nasally delivered drug products. Leyden Labs’ platform targets commonalities of viral families to develop product candidates that protect against many strains of a virus simul- taneously with a single product. Its easy-to-use nasal spray product candidates may allow people to immediately protect themselves against infec- tion and transmission of known and new viruses, protecting humanity from the devastating effects of future pandemics and recurring seasonal out- breaks such as influenza and coronaviruses. Nanopharm will screen and subsequently develop a liquid nasal spray formulation, including per- formance testing and nasal deposition studies, to prepare Leyden Labs for Phase 1 clinical studies. Formulation approaches utilising muco-adhesive technologies will be part of the development pro- cess to try to achieve maximum deposition and retention in the nasal cavity. In parallel, a powder system may also be assessed to provide long-term stability. All formulation development will be per- formed at Nanopharm’s facility in Newport, United Kingdom, which houses its R&D laboratories for formulation and characterisation of inhaled and nasal products, supporting start-up bio- tech, big pharma or generic companies globally. October - 2021 / The Pharmaceutical Post 08 15 ESENOREV neitsabéS ©SWEN